Following careful review of all nominations for open positions on the RAPS board of directors 2018–2020 term, the RAPS nominating committee announced the slate of officers and directors to join the board for its next term. Following are the incoming board members:

President-elect:

• Glenn Byrd, MBA, RAC
  Senior Director, Promotional Regulatory Affairs
  AstraZeneca

Directors:

• Raina Dauria, MS, RAC
  Senior Director, Regulatory Affairs
  Ethicon Inc., a Johnson & Johnson Family Company
• Laila Gurney, MS, RAC
  Head of Global Regulatory Affairs
  GE Healthcare
• Nancy Singer, JD, LLM, RAC, FRAPS
  President
  Compliance-Alliance LLC
• Susan Stewart, JD, RAC, FRAPS
  Regulatory Consultant
  Stewart Regulatory Consulting LLC

“The committee has selected a distinguished group of members to serve on the board, beginning 1 January 2018. These individuals have the knowledge, visibility, depth and breadth of experience, and commitment necessary to serve the organization well into the future. We are very encouraged by these regulatory professionals who are so enthusiastic and eager to serve in such an important leadership capacity,” wrote the nominating committee in its letter to RAPS members.

In accordance with RAPS bylaws, RAPS members may submit additional nominations through written petition, which must specify a qualified candidate’s name and position sought and must bear the names, contact information and signatures of at least 50 active and life members in good standing. Any petitions must be submitted electronically to the RAPS nominating committee via nominations@raps.org by 14 July 2017. If no nomination petitions are received, the slate of incoming board members will be confirmed on 17 July 2017.